Resource Summary Report

Generated by dkNET on Aug 5, 2026

RNA polymerase II CTD repeat YSPTSPS antibody [8WG16] - ChIP Grade

RRID:AB_306327
Type: Antibody

Proper Citation

Abcam Cat# ab817, RRID:AB_306327

Antibody Information

URL: http://antibodyregistry.org/AB_306327

Proper Citation: Abcam Cat# ab817, RRID:AB_306327

Target Antigen: RNA polymerase II CTD repeat YSPTSPS antibody [8WG16] - ChIP Grade

Host Organism: mouse

Clonality: monoclonal

Comments: validation status unknown, seller recommendations provided in 2012:2a;2a ChIP, CHIPseq, ICC, IP, P, WB; Other; Western Blot; ChIP; Chromatography; Immunoprecipitation; Immunocytochemistry

Antibody Name: RNA polymerase II CTD repeat YSPTSPS antibody [8WG16] - ChIP Grade

Description: This monoclonal targets RNA polymerase II CTD repeat YSPTSPS antibody [8WG16] - ChIP Grade

Target Organism: xenopusamphibian, cow, yeastfungi, mouse, plant, bovine, human

Antibody ID: AB_306327

Vendor: Abcam

Catalog Number: ab817

Record Creation Time: 20250820T034700+0000

Record Last Update: 20250820T171033+0000

Ratings and Alerts

- ENCODE PROJECT External validation for lot: 346588 is available under ENCODE ID: ENCAB437VHB - ENCODE https://www.encodeproject.org/antibodies/ENCAB437VHB

No alerts have been found for RNA polymerase II CTD repeat YSPTSPS antibody [8WG16] - ChIP Grade.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 49 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Devlin JR, et al. (2025) A CDK11-dependent RNA polymerase II pause-checkpoint precedes CDK9-mediated transition to transcriptional elongation. Molecular cell, 85(17), 3256.

Chovatiya G, et al. (2025) Cell-type-specific RNA polymerase II activity maps in intact tissues provide a gateway to mammalian gene regulatory mechanisms in vivo. Developmental cell.

Becht DC, et al. (2024) The winged helix domain of MORF binds CpG islands and the TAZ2 domain of p300. iScience, 27(4), 109367.

Zhao H, et al. (2024) An IDR-dependent mechanism for nuclear receptor control of Mediator interaction with RNA polymerase II. Molecular cell, 84(14), 2648.

Mustafa EH, et al. (2024) Selective inhibition of CDK9 in triple negative breast cancer. Oncogene, 43(3), 202.

Pappas G, et al. (2023) MDC1 maintains active elongation complexes of RNA polymerase II. Cell reports, 42(1), 111979.

André KM, et al. (2023) Functional interplay between Mediator and RSC chromatin remodeling complex controls nucleosome-depleted region maintenance at promoters. Cell reports, 42(5), 112465.

Perurena N, et al. (2023) USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities. Cell reports. Medicine, 4(4), 101007.

Meeuse MWM, et al. (2023) C. elegans molting requires rhythmic accumulation of the Grainyhead/LSF transcription factor GRH-1. The EMBO journal, 42(4), e111895.

Ouyang X, et al. (2023) Bacterial effector restricts liquid-liquid phase separation of ZPR1 to antagonize host UPRER. Cell reports, 42(7), 112700.

Miao L, et al. (2022) The landscape of pioneer factor activity reveals the mechanisms of chromatin reprogramming and genome activation. Molecular cell, 82(5), 986.

Liu N, et al. (2022) A lncRNA fine-tunes salicylic acid biosynthesis to balance plant immunity and growth. Cell host & microbe, 30(8), 1124.

Moorhouse AJ, et al. (2022) The BASP1 transcriptional corepressor modifies chromatin through lipid-dependent and lipid-independent mechanisms. iScience, 25(8), 104796.

Morao AK, et al. (2022) Topoisomerases I and II facilitate condensin DC translocation to organize and repress X chromosomes in C. elegans. Molecular cell, 82(22), 4202.

Vervoort SJ, et al. (2021) The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer. Cell, 184(12), 3143.

Forey R, et al. (2021) A Role for the Mre11-Rad50-Xrs2 Complex in Gene Expression and Chromosome Organization. Molecular cell, 81(1), 183.

Yu M, et al. (2021) Interferon-? induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation. Molecular cell, 81(6), 1216.

Narita T, et al. (2021) Enhancers are activated by p300/CBP activity-dependent PIC assembly, RNAPII recruitment, and pause release. Molecular cell, 81(10), 2166.

Kim B, et al. (2021) Neuronal activity-induced BRG1 phosphorylation regulates enhancer activation. Cell reports, 36(2), 109357.

Estell C, et al. (2021) ZC3H4 restricts non-coding transcription in human cells. eLife, 10.